Associate, Litigation Department
New YorkPhone: 1(212) 318-6740
Amanda Hoffman, Ph.D. is an associate in the Litigation practice of Paul Hastings and is based in the New York office. Her practice primarily focuses on intellectual property law, particularly patent litigation matters in the fields of pharmaceuticals and biotechnology. Dr. Hoffman has experience litigating cases arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA) for major pharmaceutical companies. She has represented life science companies in litigations involving new pharmaceutical compounds, pharmaceutical formulations, antibody technology, and polymorph crystal forms.
Dr. Hoffman served as a court law clerk to Judge Leonard P. Stark and Judge Richard G. Andrews of the U.S. District Court for the District of Delaware in 2020-21 before returning to the firm. During law school, Dr. Hoffman worked as a legal intern for the Committee on Grievances in the U.S. District Court for the Southern District of New York to Judge P. Kevin Castel and Judge Katherine B. Forrest. She also served as a judicial intern to Judge Joanna Seybert of the U.S. District Court for the Eastern District of New York.
Dr. Hoffman received her J.D. from St. John’s University School of Law, where she served as Executive Articles Editor of the American Bankruptcy Institute Law Review Journal. She obtained her Ph.D. from Syracuse University in bioinorganic and medicinal chemistry, and graduated with a B.S. in chemistry from Binghamton University, cum laude.
- St. John's University School of Law, J.D., 2017
- Syracuse University, Ph.D., 2014
- Syracuse University, M. Phil., 2011
- Binghamton University, B.S., 2009
- Boehringer Ingelheim in BPCIA patent litigation relating to the company's request to market Cyltezo® (adalimumab-abdm), a biosimilar of Humira® (adalimumab).
- Onyx Therapeutics in Hatch-Waxman patent litigation involving generic challenge to Kyprolis® (carfilzomib), an innovative treatment used for multiple myeloma.
Engagement & Publications
- Hoffman, A. E.; DeStefano, M.; Shoen, C.; Gopinath, K.; Warner, D. F.; Cynamon, M.; Doyle, R. P. Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis. Eur. J. Med. Chem., 2013, 70: 589-593
- Bankruptcy Court Enforces 20-Year Old Orders Barring Asbestos Claims Against Insurance Company, ABI BANKR. CASE BLOG, (Dec. 29, 2015).
- Ferromagnetic Coupling in "Double-Bridged" Dihydrogenpyrophosphate Complexes of Cobalt (II) and Nickel (II). Inorg. Chem. 2015, 54: 6537-6546.
- Clinical isolates of Candida albicans, Candida tropicalis, and Candida krusei have different susceptibilities to Co(II) and Cu(II) complexes. Biometals, 2015, 28: 415-423.
- Co(II) and Cu(II) pyrophosphate complexes have selectivity and potency against Mycobacteria including Mycobacterium tuberculosis. Eur. J. Med. Chem., 2013, 70: 589-593.
- Synthesis, structural, thermal, and magnetic investigations of Co(II), Ni(II), and Mn(II) pyrophosphate chains. InorganicaChimicaActa, 2012, 389: 151-158.
- Thioamide, urea, and thiourea bridged rhenium(I) complexes as luminescent anion receptors. InorganicaChimicaActa, 2011, 374: 558-565.
- Expanding monomeric pyrophosphate complexes beyond platinum. Inorg. Chem., 2010, 49: 6790-6792.